Precision medicine holds promise of a healthier society and creates targeted therapies for serious and chronic diseases. However, some targeted therapies are more targeted than others. Often, patients are devastated by the absence of a therapy or experience incomplete cure.
For this reason, Linkster Therapeutics aims at transforming targeted therapy with translational antibody engineering in tissue and living organisms. In fact, our unique Flycode® platform profiles large pools of peptide barcoded antibodies in vitro, in vivo and in silico. As a result, we innovate pharmacology profiling and accelerate the development of antibody drugs to create the next generation of precision medicines.